(self.webpackChunknatco_cal_prod=self.webpackChunknatco_cal_prod||[]).push([[580],{5580:(e,t,o)=>{"use strict";o.r(t),o.d(t,{Calculator4Module:()=>p});var r=o(1116),a=o(2935),n=o(4369),i=o(2006),s=o(1041),c=o(5366),l=o(2797),u=o(7436);function g(e,t){if(1&e&&(c.TgZ(0,"td"),c._uU(1),c.TgZ(2,"sup"),c._uU(3,"3"),c.qZA(),c.qZA()),2&e){const e=c.oxw();c.xp6(1),c.hij(" ",e.treat_recom,"")}}function d(e,t){if(1&e&&(c.TgZ(0,"td"),c._uU(1),c.qZA()),2&e){const e=c.oxw();c.xp6(1),c.Oqu(e.treat_recom)}}const Z=[{path:"",component:(()=>{class e{constructor(e){this.dialog=e,this.score1="",this.score2="",this.score3="",this.score4="",this.score5="",this.score6="",this.score7="",this.score8="",this.stroke_risk=0,this.score=0,this.risk_level="-",this.throm_event_rate="-",this.treat_recom="-",this.formGroup=new s.cw({score1:new s.NI("",[s.kI.required]),score2:new s.NI("",[s.kI.required]),score3:new s.NI("",[s.kI.required]),score4:new s.NI("",[s.kI.required]),score5:new s.NI("",[s.kI.required]),score6:new s.NI("",[s.kI.required]),score7:new s.NI("",[s.kI.required]),score8:new s.NI("",[s.kI.required])})}ngOnInit(){}reset(){this.formGroup.reset(),this.score=0,this.risk_level="-",this.throm_event_rate="-",this.treat_recom="-",this.stroke_risk=0}ScoreSubmit(){this.formGroup.valid?(console.log(this.formGroup.value),localStorage.setItem("cal4_detail",JSON.stringify(this.formGroup.value)),this.score=parseInt(this.formGroup.value.score1)+parseInt(this.formGroup.value.score2)+parseInt(this.formGroup.value.score3)+parseInt(this.formGroup.value.score4)+parseInt(this.formGroup.value.score5)+parseInt(this.formGroup.value.score6)+parseInt(this.formGroup.value.score7)+parseInt(this.formGroup.value.score8),console.log(this.score),0==this.score?(this.risk_level="Low",this.throm_event_rate="0%",this.treat_recom="No antithrombotic treatment"):1==this.score?(this.risk_level="Intermediate",this.throm_event_rate="0.46-2.8%",this.treat_recom="Oral anticoagulant is recommended for stroke prevention in AF (Class II, level B); Non-vitamin K antagonist oral anticoagulants (NOACs) are recommended in preference to VKAs (Class I, level A). VKA with INR goal 2.0\u20133.0 in patients with mechanical heart valves or moderate-to-severe mitral stenosis (Class I, level B)."):(this.risk_level="High",this.throm_event_rate="3.0-5.0%",this.treat_recom="Oral anticoagulant is recommended for stroke prevention in AF (Class I, level A); Non-vitamin K antagonist oral anticoagulants (NOACs) are recommended in preference to VKAs (Class I, level A). VKA with INR goal 2.0\u20133.0 in patients with mechanical heart valves or moderate-to-severe mitral stenosis (Class I, level B)."),this.stroke_risk=0==this.score?0:1==this.score?1.3:2==this.score?2.2:3==this.score?3.2:4==this.score?4:5==this.score?6.7:6==this.score?9.8:7==this.score?9.6:8==this.score?6.7:15.2,localStorage.setItem("cal4_score",JSON.stringify({Score:this.score,"Risk level/Adjusted Stroke Risk":this.risk_level+"/"+this.stroke_risk,"Thromboembolic event rate":this.throm_event_rate,"Treatment Recommendations (ESC guidelines 2010)":this.treat_recom}))):alert("Please fill all details")}}return e.\u0275fac=function(t){return new(t||e)(c.Y36(a.uw))},e.\u0275cmp=c.Xpm({type:e,selectors:[["app-calculator4"]],decls:173,vars:7,consts:[[1,"container-fluid","page"],[1,"header"],[1,"content"],[1,"secondcard"],[3,"formGroup","ngSubmit"],[1,"row"],[1,"col-sm-5"],[1,"p-tag"],[1,"radiobtn"],["aria-label","Select an option","formControlName","score1"],["value","1"],["value","0"],["aria-label","Select an option","formControlName","score2"],["aria-label","Select an option","formControlName","score3"],["value","2"],["aria-label","Select an option","formControlName","score4"],[1,"col-sm-7"],["aria-label","Select an option","formControlName","score5"],["aria-label","Select an option","formControlName","score6"],["aria-label","Select an option","formControlName","score7"],["aria-label","Select an option","formControlName","score8"],["mat-stroked-button","","type","submit"],[1,"clear-btn"],["mat-stroked-button","",1,"clear",3,"click"],[1,"inter-head"],[1,"table-responsive"],[1,"table"],[1,"res_table"],[4,"ngIf","ngIfElse"],["withoutsup",""],[1,"disc_def"],[1,"disclaimer"],[1,"disc_head"],[1,"reference"],[1,"ref_head"],[1,"ref_def"]],template:function(e,t){if(1&e&&(c.TgZ(0,"div",0),c.TgZ(1,"mat-card"),c.TgZ(2,"mat-card-title",1),c._uU(3,"CHA"),c.TgZ(4,"sub"),c._uU(5,"2"),c.qZA(),c._uU(6,"DS"),c.TgZ(7,"sub"),c._uU(8,"2"),c.qZA(),c._uU(9,"-VASc Score for Stroke Risk Assessment in Atrial Fibrillation "),c.qZA(),c.TgZ(10,"mat-card-content",2),c._uU(11," The CHADS"),c.TgZ(12,"sub"),c._uU(13,"2"),c.qZA(),c._uU(14," score (congestive heart failure, hypertension, age \u226575 years, diabetes mellitus, stroke [double weight]) was developed to more accurately predict the risk of stroke in patients with nonrheumatic atrial fibrillation. Consequently, CHADS"),c.TgZ(15,"sub"),c._uU(16,"2"),c.qZA(),c._uU(17," was expanded to include three additional independent risk factors: vascular disease (coronary artery disease, peripheral artery disease, aortic atherosclerosis), age 65-74 years, and female sex. This new, more inclusive scoring system is the CHA"),c.TgZ(18,"sub"),c._uU(19,"2"),c.qZA(),c._uU(20,"DS"),c.TgZ(21,"sub"),c._uU(22,"2"),c.qZA(),c._uU(23,"-VASc score. The 2016 European Society of Cardiology (ESC) guidelines recommend using the CHA"),c.TgZ(24,"sub"),c._uU(25,"2"),c.qZA(),c._uU(26,"DS"),c.TgZ(27,"sub"),c._uU(28,"2"),c.qZA(),c._uU(29,"-VASc score to estimate stroke risk in AF patients and to start oral anticoagulant (OAC) in men with a score of 1 or higher and women with a score of 2 or higher."),c.TgZ(30,"sup"),c._uU(31,"1, 2"),c.qZA(),c.qZA(),c.qZA(),c.TgZ(32,"mat-card",3),c.TgZ(33,"form",4),c.NdJ("ngSubmit",function(){return t.ScoreSubmit()}),c.TgZ(34,"div",5),c.TgZ(35,"div",6),c.TgZ(36,"p",7),c.TgZ(37,"span"),c._uU(38,"Congestive heart failure"),c.qZA(),c.TgZ(39,"span",8),c.TgZ(40,"mat-radio-group",9),c.TgZ(41,"mat-radio-button",10),c._uU(42,"Yes"),c.qZA(),c.TgZ(43,"mat-radio-button",11),c._uU(44,"No"),c.qZA(),c.qZA(),c.qZA(),c.qZA(),c.TgZ(45,"p",7),c.TgZ(46,"span"),c._uU(47,"Hypertension"),c.qZA(),c.TgZ(48,"span",8),c.TgZ(49,"mat-radio-group",12),c.TgZ(50,"mat-radio-button",10),c._uU(51,"Yes"),c.qZA(),c.TgZ(52,"mat-radio-button",11),c._uU(53,"No"),c.qZA(),c.qZA(),c.qZA(),c.qZA(),c.TgZ(54,"p",7),c.TgZ(55,"span"),c._uU(56,"Age \u226575 years"),c.qZA(),c.TgZ(57,"span",8),c.TgZ(58,"mat-radio-group",13),c.TgZ(59,"mat-radio-button",14),c._uU(60,"Yes"),c.qZA(),c.TgZ(61,"mat-radio-button",11),c._uU(62,"No"),c.qZA(),c.qZA(),c.qZA(),c.qZA(),c.TgZ(63,"p",7),c.TgZ(64,"span"),c._uU(65,"Diabetes mellitus"),c.qZA(),c.TgZ(66,"span",8),c.TgZ(67,"mat-radio-group",15),c.TgZ(68,"mat-radio-button",10),c._uU(69,"Yes"),c.qZA(),c.TgZ(70,"mat-radio-button",11),c._uU(71,"No"),c.qZA(),c.qZA(),c.qZA(),c.qZA(),c.qZA(),c.TgZ(72,"div",16),c.TgZ(73,"p",7),c.TgZ(74,"span"),c._uU(75,"Stroke/Transient Ischemic Attack/Thromboembolic event"),c.qZA(),c.TgZ(76,"span",8),c.TgZ(77,"mat-radio-group",17),c.TgZ(78,"mat-radio-button",14),c._uU(79,"Yes"),c.qZA(),c.TgZ(80,"mat-radio-button",11),c._uU(81,"No"),c.qZA(),c.qZA(),c.qZA(),c.qZA(),c.TgZ(82,"p",7),c.TgZ(83,"span"),c._uU(84,"Vascular disease (prior MI, PAD, or aortic plaque)"),c.qZA(),c.TgZ(85,"span",8),c.TgZ(86,"mat-radio-group",18),c.TgZ(87,"mat-radio-button",10),c._uU(88,"Yes"),c.qZA(),c.TgZ(89,"mat-radio-button",11),c._uU(90,"No"),c.qZA(),c.qZA(),c.qZA(),c.qZA(),c.TgZ(91,"p",7),c.TgZ(92,"span"),c._uU(93,"Age 65 to 74 years"),c.qZA(),c.TgZ(94,"span",8),c.TgZ(95,"mat-radio-group",19),c.TgZ(96,"mat-radio-button",10),c._uU(97,"Yes"),c.qZA(),c.TgZ(98,"mat-radio-button",11),c._uU(99,"No"),c.qZA(),c.qZA(),c.qZA(),c.qZA(),c.TgZ(100,"p",7),c.TgZ(101,"span"),c._uU(102,"Sex category (ie, female sex)"),c.qZA(),c.TgZ(103,"span",8),c.TgZ(104,"mat-radio-group",20),c.TgZ(105,"mat-radio-button",10),c._uU(106,"Yes"),c.qZA(),c.TgZ(107,"mat-radio-button",11),c._uU(108,"No"),c.qZA(),c.qZA(),c.qZA(),c.qZA(),c.qZA(),c.qZA(),c.TgZ(109,"div"),c.TgZ(110,"p",7),c.TgZ(111,"span"),c.TgZ(112,"button",21),c._uU(113,"Submit"),c.qZA(),c.qZA(),c.TgZ(114,"span",22),c.TgZ(115,"span",23),c.NdJ("click",function(){return t.reset()}),c._uU(116,"Clear"),c.qZA(),c.qZA(),c.qZA(),c._UZ(117,"hr"),c.TgZ(118,"p",24),c._uU(119,"Interpretation"),c.qZA(),c.TgZ(120,"div",25),c.TgZ(121,"table",26),c.TgZ(122,"tr",27),c.TgZ(123,"th"),c._uU(124,"Total score"),c.qZA(),c.TgZ(125,"th"),c._uU(126,"Risk level/Adjusted Stroke Risk (% per year)"),c.qZA(),c.TgZ(127,"th"),c._uU(128,"Thromboembolic event rate"),c.qZA(),c.TgZ(129,"th"),c._uU(130,"Treatment Recommendations (ESC guidelines 2010)"),c.qZA(),c.qZA(),c.TgZ(131,"tr"),c.TgZ(132,"td"),c._uU(133),c.qZA(),c.TgZ(134,"td"),c._uU(135),c.qZA(),c.TgZ(136,"td"),c._uU(137),c.qZA(),c.YNc(138,g,4,1,"td",28),c.YNc(139,d,2,1,"ng-template",null,29,c.W1O),c.qZA(),c.qZA(),c.qZA(),c.qZA(),c.qZA(),c.TgZ(141,"p",30),c._uU(142," ESC = European Society of Cardiology; VKA = vitamin K antagonist; INR = international normalized ratio. "),c.qZA(),c.TgZ(143,"div",31),c.TgZ(144,"p",32),c._uU(145,"Disclaimer:"),c.qZA(),c.TgZ(146,"span",30),c._uU(147,"Calculations alone should never dictate patient care, and are no substitute for professional judgement."),c.qZA(),c.qZA(),c.TgZ(148,"div",33),c.TgZ(149,"p",34),c._uU(150,"References:"),c.qZA(),c.TgZ(151,"ol",35),c.TgZ(152,"li"),c._uU(153," CHADS"),c.TgZ(154,"sub"),c._uU(155,"2"),c.qZA(),c._uU(156," Score for Stroke Risk Assessment in Atrial Fibrillation. Accessed May 23, 2021. https://emedicine.medscape.com/article/2172597-overview. "),c.qZA(),c.TgZ(157,"li"),c._uU(158," Odum LE, Cochran KA, Aistrope DS, Snella KA. The CHADS"),c.TgZ(159,"sub"),c._uU(160,"2"),c.qZA(),c._uU(161," versus the new CHA"),c.TgZ(162,"sub"),c._uU(163,"2"),c.qZA(),c._uU(164,"DS"),c.TgZ(165,"sub"),c._uU(166,"2"),c.qZA(),c._uU(167,"-VASc scoring systems for guiding antithrombotic treatment of patients with atrial fibrillation: review of the literature and recommendations for use. "),c.TgZ(168,"i"),c._uU(169,"Pharmacotherapy"),c.qZA(),c._uU(170,". 2012;32(3):285-296. "),c.qZA(),c.TgZ(171,"li"),c._uU(172," Hindricks G, Potpara T, Dagres N, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J. 2021;42(5):373-498. "),c.qZA(),c.qZA(),c.qZA(),c.qZA(),c.qZA()),2&e){const e=c.MAs(140);c.xp6(33),c.Q6J("formGroup",t.formGroup),c.xp6(100),c.Oqu(t.score),c.xp6(2),c.AsE("",t.risk_level,"/",t.stroke_risk,""),c.xp6(2),c.Oqu(t.throm_event_rate),c.xp6(1),c.Q6J("ngIf","-"!=t.treat_recom)("ngIfElse",e)}},directives:[l.a8,l.n5,l.dn,s._Y,s.JL,s.sg,u.VQ,s.JJ,s.u,u.U0,n.lW,r.O5],styles:[".mat-card[_ngcontent-%COMP%]:not([class*=mat-elevation-z]){box-shadow:0 0 20px 0 #0003,0 5px 5px 0 #0000003d}.page[_ngcontent-%COMP%]{padding-top:1rem;background:#fff}.header[_ngcontent-%COMP%], .pat_header[_ngcontent-%COMP%]{color:#005baa;font-weight:600;font-family:poppins;font-size:20px}.content[_ngcontent-%COMP%]{color:#707070;font-size:15px;line-height:25px;text-align:justify}.mat-card.patient_card[_ngcontent-%COMP%], .mat-card.secondcard[_ngcontent-%COMP%]{margin-top:25px}.res_table[_ngcontent-%COMP%]{border-collapse:collapse;border-radius:1px solid}td[_ngcontent-%COMP%], th[_ngcontent-%COMP%]{border:1px solid #e4e4e4;text-align:center;color:#707070}th[_ngcontent-%COMP%]{background-color:#efefef}.radiobtn[_ngcontent-%COMP%]{float:right} .mat-radio-outer-circle{border-color:#bebebe} .mat-radio-button.mat-accent .mat-radio-inner-circle{background-color:#2e3192} .mat-radio-button.mat-accent.mat-radio-checked .mat-radio-outer-circle{border-color:#bebebe}.mat-radio-inner-circle[_ngcontent-%COMP%],  .mat-radio-checked{transform:scale(1)}.mat-radio-button[_ngcontent-%COMP%] ~ .mat-radio-button[_ngcontent-%COMP%]{margin-left:16px}.p-tag[_ngcontent-%COMP%]{color:#707070;font-size:15px}span.clear-btn[_ngcontent-%COMP%]{border-radius:4px;padding:8px 16px 8.2px;font-size:14px;font-weight:500;cursor:pointer;border:1px solid #8080803d;background-color:#ee1e24;color:#fff}.clear[_ngcontent-%COMP%]{box-shadow:0 0 0 0 #0003,0 0 0 0 #00000024,0 0 0 0 #0000001f}.clear-btn[_ngcontent-%COMP%]{margin-left:10px}.inter-head[_ngcontent-%COMP%]{color:#005baa;font-weight:600;font-size:20px;font-family:poppins}.disc_head[_ngcontent-%COMP%], .ref_head[_ngcontent-%COMP%]{color:#005baa;font-weight:600;font-size:16px;font-family:poppins}.disc_def[_ngcontent-%COMP%], .ref_def[_ngcontent-%COMP%]{color:#707070;font-size:14px}.disclaimer[_ngcontent-%COMP%], .reference[_ngcontent-%COMP%]{margin-top:15px}button.mat-focus-indicator.mat-stroked-button.mat-button-base[_ngcontent-%COMP%]{background-color:#005baa;color:#fff}.i-icon[_ngcontent-%COMP%]{cursor:pointer}.patient[_ngcontent-%COMP%]{padding:0 15px;border-color:#80808026;border-radius:4px;background-color:#ee1e24;color:#fff;margin-bottom:10px}.inputbox[_ngcontent-%COMP%]{border:1px solid gray}"]}),e})()}];let m=(()=>{class e{}return e.\u0275fac=function(t){return new(t||e)},e.\u0275mod=c.oAB({type:e}),e.\u0275inj=c.cJS({imports:[[i.Bz.forChild(Z)],i.Bz]}),e})(),p=(()=>{class e{}return e.\u0275fac=function(t){return new(t||e)},e.\u0275mod=c.oAB({type:e}),e.\u0275inj=c.cJS({imports:[[r.ez,m,a.Is,n.ot]]}),e})()}}]);